EFFECT OF THE COMPLEXITY OF THE DRUG REGIMEN ON ADHERENCE IN HIV INFECTED PATIENTS
DI-043
APPROPRIATENESS OF TELAPREVIR TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1
DI-037
COMPARISON OF INDIRECT TREATMENT FOR FIRST-LINE METASTATIC PANCREATIC CANCER
DI-034
NEUROLOGICAL TOXICITY CAUSED BY IFOSFAMIDE IN CHILDREN
DI-033
SAFETY PROFILE STUDY OF PLANNED RANDOMISED CONVERSION FROM TACROLIMUS TO SIROLIMUS-BASED IMMUNOSUPPRESSIVE REGIMEN IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
DI-032
OMALIZUMAB USE: OUR EXPERIENCE IN A REGIONAL HOSPITAL
DI-031
EFFECTIVENESS AND SAFETY OF ABIRATERONE IN PROSTATE CANCER IN CLINICAL PRACTICE
DI-030
PRESCRIPTION PROFILE OF ABIRATERONE IN METASTATIC PROSTATE CARCINOMA
DI-029
USE OF ERYTHROPOIESIS-STIMULATING AGENTS AFTER THE CESSATION OF SUPPLY OF CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR
DI-028
PHARMACOTHERAPY PROFILE OF HIV-PATIENTS OLDER THAN 50 YEARS IN USE OF ANTIRETROVIRAL THERAPY
DI-027
QUALITY OF LIFE IN OLDER HIV-INFECTED PATIENTS WITH ANTIRETROVIRAL THERAPY
DI-024
CETUXIMAB IN THE TREATMENT OF ADVANCED METASTATIC COLORECTAL CANCER
DI-023
INFORMATION ABOUT THE ANTICANCER CHEMOTHERAPY PROCESS: A FILM FOR PATIENTS
DI-017
SAFETY OF NAB-PACLITAXEL PLUS GEMCITABINE IN PATIENTS WITH METASTATIC PANCREATIC CANCER
DI-016
REGIONAL CARD FOR THE PRESCRIPTION OF BOTULINUM TOXIN BY CLOSTRIDIUM BOTULINUM TYPE A: AN INSTRUMENT FOR APPROPRIATE PRESCRIBING
